Advertisement

Topics

Pfizer and Mount Sinai Renew Agreement to Identify New Drug Candidates

06:00 EDT 3 Jul 2017 | PharmPro

Mount Sinai, Pfizer renew research collaboration, building on strong foundation. The researchers take aim at major diseases, such as cancer, rheumatoid arthritis, Crohn's disease, colitis, heart failure, Alzheimer's disease, and cystic fibrosis.
Contributed Author: 
The Mount Sinai Hospital/Mount Sinai School of Medicine

Original Article: Pfizer and Mount Sinai Renew Agreement to Identify New Drug Candidates

NEXT ARTICLE

More From BioPortfolio on "Pfizer and Mount Sinai Renew Agreement to Identify New Drug Candidates"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...